High Court Won't Hear Generic MS Drug Patent Challenge
The U.S. Supreme Court on Monday declined to review the Federal Circuit's decision not to let Argentum Pharmaceuticals appeal its failed attempt to challenge a Novartis patent, unmoved by arguments that...To view the full article, register now.
Already a subscriber? Click here to view full article